SC 13G/A | 2020-07-22 | MFN Partners Management, LP | Aclaris Therapeutics, Inc. | 1,895,677 | 4.5% | EDGAR |
SC 13G/A | 2020-07-10 | BlackRock Inc. | Aclaris Therapeutics, Inc. | 1,047,816 | 2.5% | EDGAR |
SC 13G | 2020-06-26 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Aclaris Therapeutics, Inc. | 2,500,000 | 6.0% | EDGAR |
SC 13G/A | 2020-03-09 | MORGAN STANLEY | Aclaris Therapeutics, Inc. | 23,767 | 0.1% | EDGAR |
SC 13G | 2020-03-06 | Samsara BioCapital, L.P. | Aclaris Therapeutics, Inc. | 2,161,333 | 5.2% | EDGAR |
SC 13G/A | 2020-02-14 | D. E. SHAW & CO, L.P. | Aclaris Therapeutics, Inc. | 69,769 | 0.2% | EDGAR |
SC 13G/A | 2020-02-14 | Rock Springs Capital Management LP | Aclaris Therapeutics, Inc. | 1,600,000 | 3.9% | EDGAR |
SC 13G | 2020-02-14 | EcoR1 Capital, LLC | Aclaris Therapeutics, Inc. | 2,087,312 | 5.0% | EDGAR |
SC 13G/A | 2020-02-13 | MORGAN STANLEY | Aclaris Therapeutics, Inc. | 2,518,882 | 6.1% | EDGAR |
SC 13G/A | 2020-02-13 | MFN Partners Management, LP | Aclaris Therapeutics, Inc. | 4,000,000 | 9.7% | EDGAR |
SC 13G/A | 2020-02-13 | Broadfin Capital, LLC | Aclaris Therapeutics, Inc. | 1,888,039 | 4.6% | EDGAR |
SC 13G/A | 2020-02-13 | Flynn James E | Aclaris Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G | 2020-02-12 | RENAISSANCE TECHNOLOGIES LLC | Aclaris Therapeutics, Inc. | 2,782,297 | 6.7% | EDGAR |
SC 13G/A | 2020-02-10 | Man Group plc | Aclaris Therapeutics, Inc. | 1,295,966 | 3.1% | EDGAR |
SC 13G/A | 2020-02-07 | FMR LLC | Aclaris Therapeutics, Inc. | 205,984 | 0.5% | EDGAR |
SC 13G/A | 2020-02-05 | BlackRock Inc. | Aclaris Therapeutics, Inc. | 2,639,569 | 6.4% | EDGAR |
SC 13G/A | 2020-02-04 | FRANKLIN RESOURCES INC | Aclaris Therapeutics, Inc. | 320 | 0.0% | EDGAR |
SC 13D/A | 2019-12-19 | Arkin Moshe | Aclaris Therapeutics, Inc. | 1,967,082 | 4.8% | EDGAR |
SC 13D/A | 2019-11-21 | Arkin Moshe | Aclaris Therapeutics, Inc. | 2,683,240 | 6.5% | EDGAR |
SC 13G | 2019-10-31 | MFN Partners Management, LP | Aclaris Therapeutics, Inc. | 4,000,000 | 9.7% | EDGAR |